×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Commit To Purchase Prothena Corp At $15, Earn 21.3% Using Options
Nasdaq
Investors considering a purchase of Prothena Corp plc (Symbol: PRTA) stock, but cautious about paying the going market price of $20.39/share...
4 days ago
Prothena Corp PLC Chief Accounting Officer Sells 5,000 Shares
Yahoo Finance
Karin Walker, Chief Accounting Officer of Prothena Corp PLC (NASDAQ:PRTA), sold 5000 shares of the company on January 24, 2024, according to...
3 months ago
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Business Wire
DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of...
2 months ago
Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%
Simply Wall Street
Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33% ... Prothena Corporation plc (NASDAQ:...
2 months ago
PRTA Stock Quote Price and Forecast
CNN
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of...
3 months ago
Prothena Corp PLC (PRTA) Reports Q3 2023 Financial Results
Yahoo Finance
Prothena Corp PLC (NASDAQ:PRTA), a late-stage clinical biotechnology company, released its financial results for the third quarter and first...
5 months ago
Prothena is Now Oversold (PRTA)
Nasdaq
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.
6 days ago
Prothena reports potential AL amyloidosis treatment By Investing.com
Investing.com
DUBLIN - Prothena Corporation plc (NASDAQ:PRTA), a biotechnology firm focused on protein dysregulation, has announced new findings related...
2 weeks ago
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Business Wire
Updates on PRX012 and PRX123 for treatment of Alzheimer's disease, and on birtamimab for treatment of AL amyloidosis; Remain on track with...
3 months ago
BMS Pays Combined $95M to Evotec, Prothena for Neuro-Focused Options
BioSpace
Bristol Myers Squibb is paying a total of $95 million to the two companies for exclusive global rights to programs developed within...
9 months ago